President
ID Care
Hillsborough, New Jersey, United States
Ronald G. Nahass, MD, FACP, FIDSA earned his medical degree at the University of Medicine and Dentistry of New Jersey – The Robert Wood Johnson Medical School (RWJMS) in 1982. He has earned a Master of Science degree in Healthcare Management from the Harvard University School of Public Health in 2012. He is a Clinical Professor of Medicine at the RWJMS. He is currently the President of ID Care, the largest healthcare organization providing infectious diseases specialty services in NJ with over 60 clinicians practicing in over 130 sites.
Dr. Nahass is a Fellow of the ACP, the IDSA, and SHEA. Dr. Nahass was an active member of the clinical affairs committee of IDSA for 5 years, serving on both the value and quality subcommittees. He is the immediate past Chairman of the Quality Committee of the IDSA and was the Co-Chair of the Governance Task Force of the IDSA. He was awarded the Distinguished Physician Humanitarian Award for his work with HIV/AIDS patients by the Princeton HealthCare System in 2008. He was selected to the IDSA/AASLD Hepatitis C guidelines committee and served on that panel from November 2015 to February 2018. Dr. Nahass was honored in October 2020 by the Infectious Diseases Society of America Watanakunakorn Clinician award.
At the Robert Wood Johnson Medical School, Dr Nahass is a Clinical Professor of Medicine who volunteers his time in numerous clinical teaching roles. He is a patient centered medical home mentor for first- and second-year medical students in his office. He is a clinical research mentor for 2nd year medical students for their summer research elective. He is a preceptor for internal medicine residents in the medical clinic. He has received the Volunteer Faculty Award from RWJMS many times for his teaching.
Disclosure(s): Abbvie: Honoraria; Arbutus: Grant/Research Support; Gilead Sciences, Inc.: Grant/Research Support; Merck: Grant/Research Support; Vir: Grant/Research Support
577 - Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir
Saturday, October 19, 2024
2:09 PM – 2:21 PM US PT